Oviva Therapeutics, a premier biotech company dedicated to addressing the vast unmet need in women’s health by developing first-in-class therapeutics to preserve ovarian function and consequently extend female healthspan, today announced the appointment of Rachel Rimsky Rubin as its new Chief Operating Officer.
New efforts to boost women’s health and extend fertility depend on developing tools to slow the aging of ovaries.
Startup founders are rushing to tackle menopause’s worst symptoms, sniffing a $16 billion opportunity. Others are trying to eliminate menopause altogether. Oviva is one of a handful of biotech startups working toward therapeutics that would end menopause as we know it, or at the very least give women better options for managing their fertility.
Daisy Robinton, PhD, met with the Oprah Daily team to bring the conversation around unmet needs in womens health, and the efforts Oviva Therapeutics is making through innovative biomedical research to improve this, into public discourse.
Daisy Robinton, the cofounder and CEO of Oviva Therapeutics maintains that the lack of scientific research on women’s bodies means there’s a lack of information, resources, and education for women’s health.
Women’s health and ovarian health are closely intertwined. Daisy Robinton is determined to improve women’s wellbeing by studying the possibility of lengthening the lifespan of the ovaries – which could mean breakthroughs in menopause and fertility research.
Oviva’s mission is to address the vast unmet need in women’s health by driving research and clinical development targeting ovarian physiology, and by expanding funding and awareness in this space. Age-related decline in ovarian function leads to adverse health outcomes in women across the board. Oviva aims to extend healthspan in women through developing novel therapeutics that target ovarian function and longevity.
Reproductive science is quickly changing, as is society’s approach to the issues around fertility. Daisy Robinton the CEO of Oviva Therapeutics weighs in with her outlook on the future of fertility.
Oviva Therapeutics addresses the vast unmet need in women's health by expanding funding, research and clinical development of treatments addressing female physiology, beginning with a focus on ovarian aging.
There aren’t many biotechs emphasizing women’s health, but a new spinout is trying to change that.
The field of female reproductive longevity and inequality is getting more and more attention.
Led by Daisy Robinton, PhD, Oviva aims to improve ovarian health and extend female healthspan through therapeutic innovation
Oviva Therapeutics just raised $11.5 million to develop drugs based on the work of Mass. General researchers.
Leaders in the fertility industry discuss male fertility treatment, menopause and the latest breakthroughs giving people new ways to become parents.
This study aims to identify drugs that activate the Mullerian inhibiting substance pathway to be used for contraception or other applications in women’s health.
A $25 million prize awaits the discoverer of a nonsurgical sterilant for dogs and cats, but reproductive biology is complicated.
We hear from David, Associate Director of the Pediatric Surgical Research Laboratories of the Massachusetts General Hospital, and an Associate Professor of Surgery at Harvard Medical School, who speaks to the award-winning project seeking to extend the reproductive longevity and hormonal health of women as they age.
This biotech CEO wants to slow women’s aging by extending ovulation.
Cambrian’s Dr. Daisy Robinton on the basis of sex, ovarian aging and improving clinical trials and education.
One of the world’s most influential reproductive scientists, Patricia Kilroy Donahoe, MD, FACS, in June received the 2021 Jacobson Innovation Award of the American College of Surgeons (ACS) during a virtual event.
The end of the pandemic is tantalisingly close, but what about the next pandemic? Have we learnt enough to prevent it from happening?
Biomedical research and healthcare are plagued by historic sex and gender disparities. But a new dawn is on the horizon — and we’re running towards it at full speed. Watch this conversation between Daisy Robinton and Jennifer Garrison.
The group includes women who are driving innovation in therapeutics, diagnostics, sustainable foods and more.
Designed to fund early-career scientists at the peak of their creativity and inventiveness, Michelson Prizes and research grants underwrite bold, blue-sky ideas.